rodatristat ethyl
Small moleculeexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02746237)
Timeline
Indications
Mechanism of action
- Tryptophan 5-monooxygenase 1INHIBITOR
TPH1 inhibitor
- Tryptophan 5-hydroxylase 1INHIBITOR
Tryptophan 5-hydroxylase 1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)[C@@H]1CC2(CCN(c3cc(O[C@H](c4ccc(Cl)cc4-c4ccccc4)C(F)(F)F)nc(N)n3)CC2)CN1- Mol. weight
- 590.05 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL4069704 ↗
Also known as
- kar5585
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05933447 | Phase 1 | May 12, 2023 | Altasciences Company Inc., Altavant |
| NCT05684640 | Phase 1 | Sep 29, 2022 | Altavant, PPD |
| NCT05065359 | Phase 1 | Oct 1, 2021 | Altavant, Parexel |
| NCT05006118 | Phase 1 | Sep 1, 2021 | Altavant, Covance |
| NCT04712669 | Phase 2 | Mar 15, 2021 | Altavant |
| NCT02746237 | Phase 1 | Nov 1, 2015 | Karos Pharmaceuticals, Spaulding Clinical Research Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Altavant | For profit | 5 | 5 | 2 | 2021 |
| Altasciences Company Inc. | For profit | 1 | 0 | 1 | 2023 |
| Covance | For profit | 1 | 0 | 1 | 2021 |
| Karos Pharmaceuticals | For profit | 1 | 1 | 1 | 2015 |
| Parexel | For profit | 1 | 0 | 1 | 2021 |
| PPD | For profit | 1 | 0 | 1 | 2022 |
| Spaulding Clinical Research Inc. | For profit | 1 | 0 | 1 | 2015 |
7 organizations
Page 1 / 1